Concurrent versus Sequential Sorafenib Therapy in Combination with Radiation for Hepatocellular Carcinoma

Sorafenib (SOR) is the only systemic agent known to improve survival for hepatocellular carcinoma (HCC). However, SOR prolongs survival by less than 3 months and does not alter symptomatic progression. To improve outcomes, several phase I-II trials are currently examining SOR with radiation (RT) for...

Πλήρης περιγραφή

Αποθηκεύτηκε σε:
Λεπτομέρειες βιβλιογραφικής εγγραφής
Κύριοι συγγραφείς: Wild, Aaron T., Gandhi, Nishant, Chettiar, Sivarajan T., Aziz, Khaled, Gajula, Rajendra P., Williams, Russell D., Kumar, Rachit, Taparra, Kekoa, Zeng, Jing, Cades, Jessica A., Velarde, Esteban, Menon, Siddharth, Geschwind, Jean F., Cosgrove, David, Pawlik, Timothy M., Maitra, Anirban, Wong, John, Hales, Russell K., Torbenson, Michael S., Herman, Joseph M., Tran, Phuoc T.
Μορφή: Artigo
Γλώσσα:Inglês
Έκδοση: Public Library of Science 2013
Θέματα:
Research Article
Διαθέσιμο Online:https://ncbi.nlm.nih.gov/pmc/articles/PMC3675179/
https://ncbi.nlm.nih.gov/pubmed/23762417
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pone.0065726
Ετικέτες: Προσθήκη ετικέτας
Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!

Παρόμοια τεκμήρια